SISANews


Bookmark and Share

Gli acidi grassi omega-3 potenziano l'azione ipotrigliceridemizzante del fenofibrato

Sia il fenofibrato, sia gli acidi grassi omega-3 sono noti agenti ipotrigliceridemizzanti. L'aggiunta di 4 g al giorno di omega-3 alla terapia cronica con 130 mg di fenofibrato in pazienti con grave ipertrigliceridemia determina un ulteriore riduzione dei trigliceridi di circa il 17% e può essere una valida opzione nei pazienti che non rispondono a sufficienza alla monoterapia con un fibrato.

 

 

Prescription Omega-3 Fatty Acid as an Adjunct to Fenofibrate Therapy in Hypertriglyceridemic Subjects

Roth EM, Bays HE, Forker AD, Maki KC, Carter R, Doyle RT, Stein EA.

J Cardiovasc Pharmacol 2009;54:196-203

 

BACKGROUND/RATIONALE: Treatment of severe hypertriglyceridemia is indicated to reduce the risk of pancreatitis in patients with triglyceride (TG) levels >/=500 mg/dL. Hypertriglyceridemia is also a risk factor for atherosclerotic coronary heart disease. Prescription omega-3 fatty acids (P-OM3) and fenofibrate (FENO) are among the most effective lipid-altering agents that reduce TG levels. Given that some patients may not achieve optimal TG levels with a single agent, we hypothesized that concomitant use of P-OM3 or addition of P-OM3 to FENO would result in a TG reduction greater than that with FENO alone. METHODS:: This randomized, 8-week, double-blind, placebo-controlled study was designed to compare the safety and efficacy of P-OM3 4 g QD plus concomitant FENO 130 mg with FENO 130 mg QD plus placebo in subjects with very high TG levels (>/=500 mg/dL). Subjects who completed the double-blind study were given the option to continue into an open-label 8-week extension study, wherein they all received P-OM3 4 g plus FENO 130 mg QD. On completion of the first extension study, subjects were eligible to continue into an open-label 24-month extension of the treatment with P-OM3 4 g plus FENO 130 mg QD. RESULTS:: Concomitant P-OM3 + FENO (n = 81) and FENO monotherapy (n = 82) reduced median TG values from 649.5 to 267.5 mg/dL (60.8%) and from 669.3 to 310 mg/dL (53.8%), respectively (P = 0.059). When subjects who had received 8 weeks of stable FENO monotherapy were given P-OM3 during the 8-week open-label extension study (n = 58), TG levels were reduced 17.5% (P = 0.003) over the course of the extension. The second extension phase was terminated early (n = 93)-not because of a safety signal but because of the lack of a substantial incremental change in the primary endpoint lipid values above that reached in either the original study or the first extension in subjects receiving the combination of fenofibrate and P-OM3. CONCLUSIONS:: Both FENO monotherapy and P-OM3 + FENO significantly reduced TGs in subjects with very high TGs, with a trend to greater reduction in the P-OM3 + FENO group. The addition of P-OM3 to stable FENO therapy in the same subjects in an open-label extension study resulted in a statistically significant reduction in TG levels. Subjects who received P-OM3 + FENO for 16 weeks and subjects in which P-OM3 was added to FENO monotherapy during the open-label phase of the study did not differ in their final lipid responses. In the second open-label extension, within the combined group taking P-OM3 and FENO, analysis of change from the second extension baseline to end of treatment revealed no clinically important change.

 

J Cardiovasc Pharmacol 2009;54:196-203

 

Area Soci

Eventi

31° Congresso Nazionale


31° Congresso Nazionale

Palermo, 19-21 novembre 2017
Programma completo

[continua a leggere]

Congresso SISA Sezione Piemonte, Liguria e Valle d’Aosta

Genova, 2 Dicembre 2017

[continua a leggere]

Congresso Regionale SISA Sezione Campania

Napoli, 9 Novembre 2017

[continua a leggere]

Congresso Regionale SISA Sezione Lombardia

Milano, 19-21 Ottobre 2017
Assegnati i premi

[continua a leggere]

Giornale Italiano Arteriosclerosi

Rivista in lingua italiana
riservata ai Soci S.I.S.A.
Ultimo numero:
Anno 8 • N.4/2017

[continua a leggere]

Rivista NMCD

Nutrition, Metabolism and Cardiovascular Diseases

Istruzioni per l'accesso online

IF 2015: 3.390


Newsletter

Per essere informati sulle novità di S.I.S.A. iscrivetevi alla nostra newsletter inserendo
il vostro indirizzo di posta elettronica

Progetto LIPIGEN

LIPIGEN
Nuovo sito dedicato al Progetto LIPIGEN

 

Progetto LIPIGEN - Vecchio portale
E' necessario essere loggati come utente
Lipigen per poter accedere alla pagina

PROject Statin Intolerance SISA

 

PROSISA – PROject Statin Intolerance SISA
E' necessario essere loggati come utente
PROSISA per poter accedere alla pagina

GILA - Lipoprotein Aferesi

 

Gruppo Interdisciplinare Lipoprotein Aferesi
(Accesso Gruppo GILA-Lipoprotein Aferesi)

E' necessario essere loggati come utente del Gruppo GILA per poter accedere

 

Gruppo Interdisciplinare Lipoprotein Aferesi
(Documentazione ad accesso libero)

Pagina informativa per medici e pazienti